Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 10/2020

Open Access 01-10-2020 | Pancreatic Cancer | Original Article

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model

Authors: Philipp Metzger, Sabrina V. Kirchleitner, Daniel F. R. Boehmer, Christine Hörth, Angelika Eisele, Steffen Ormanns, Matthias Gunzer, Maciej Lech, Kirsten Lauber, Stefan Endres, Peter Duewell, Max Schnurr, Lars M. König

Published in: Cancer Immunology, Immunotherapy | Issue 10/2020

Login to get access

Abstract

Pancreatic ductal adenocarcinoma is characterized by a strong immunosuppressive network with a dense infiltration of myeloid cells including myeloid-derived suppressor cells (MDSC). Two distinct populations of MDSC have been defined: polymorphonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC). Several factors influence the development and function of MDSC including the transcription factor interferon regulatory factor 4 (IRF4). Here, we show that IRF4 deficiency accelerates tumor growth and reduces survival, accompanied with a dense tumor infiltration with PMN-MDSC and reduced numbers of CD8+ T cells. As IRF4 has been described to modulate myeloid cell development and function, particularly of PMN-MDSC, we analyzed its role using MDSC-specific IRF4 knockout mice with the Ly6G or LysM knock-in allele expressing Cre recombinase and Irf4flox. In GM-CSF-driven bone marrow cultures, IRF4 deficiency increased the frequency of MDSC-like cells with a strong T cell suppressive capacity. Myeloid (LysM)-specific depletion of IRF4 led to increased tumor weight and a moderate splenic M-MDSC expansion in tumor-bearing mice. PMN cell (Ly6G)-specific depletion of IRF4, however, did not influence tumor progression or MDSC accumulation in vivo in accordance with our finding that IRF4 is not expressed in PMN-MDSC. This study demonstrates a critical role of IRF4 in the generation of an immunosuppressive tumor microenvironment in pancreatic cancer, which is independent of IRF4 expression in PMN-MDSC.
Appendix
Available only for authorised users
Literature
8.
go back to reference Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ (2018) Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49(1):178–193.e177. https://doi.org/10.1016/j.immuni.2018.06.006CrossRefPubMedPubMedCentral Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ (2018) Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49(1):178–193.e177. https://​doi.​org/​10.​1016/​j.​immuni.​2018.​06.​006CrossRefPubMedPubMedCentral
9.
go back to reference Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC (2013) A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. J Cancer Ther 4(3):797–803. https://doi.org/10.4236/jct.2013.43096CrossRefPubMedPubMedCentral Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC (2013) A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. J Cancer Ther 4(3):797–803. https://​doi.​org/​10.​4236/​jct.​2013.​43096CrossRefPubMedPubMedCentral
13.
16.
go back to reference Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L, Waring JF, Bachmann MF, Zinkernagel RM, Morse HC 3rd, Ozato K, Horak I (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87(2):307–317CrossRef Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L, Waring JF, Bachmann MF, Zinkernagel RM, Morse HC 3rd, Ozato K, Horak I (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87(2):307–317CrossRef
24.
go back to reference Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, Van Gassen S, Chen J, Poidinger M, De Prijck S, Tavernier SJ, Low I, Irac SE, Mattar CN, Sumatoh HR, Low GHL, Chung TJK, Chan DKH, Tan KK, Hon TLK, Fossum E, Bogen B, Choolani M, Chan JKY, Larbi A, Luche H, Henri S, Saeys Y, Newell EW, Lambrecht BN, Malissen B, Ginhoux F (2016) Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45(3):669–684. https://doi.org/10.1016/j.immuni.2016.08.015CrossRefPubMedPubMedCentral Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, Van Gassen S, Chen J, Poidinger M, De Prijck S, Tavernier SJ, Low I, Irac SE, Mattar CN, Sumatoh HR, Low GHL, Chung TJK, Chan DKH, Tan KK, Hon TLK, Fossum E, Bogen B, Choolani M, Chan JKY, Larbi A, Luche H, Henri S, Saeys Y, Newell EW, Lambrecht BN, Malissen B, Ginhoux F (2016) Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45(3):669–684. https://​doi.​org/​10.​1016/​j.​immuni.​2016.​08.​015CrossRefPubMedPubMedCentral
25.
go back to reference Sichien D, Scott Charlotte L, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, Joeris T, De Prijck S, Vanhoutte L, Vanheerswynghels M, Van Isterdael G, Toussaint W, Madeira Filipe B, Vergote K, Agace William W, Clausen Björn E, Hammad H, Dalod M, Saeys Y, Lambrecht Bart N, Guilliams M (2016) IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells. Respect Immun 45(3):626–640. https://doi.org/10.1016/j.immuni.2016.08.013CrossRef Sichien D, Scott Charlotte L, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, Joeris T, De Prijck S, Vanhoutte L, Vanheerswynghels M, Van Isterdael G, Toussaint W, Madeira Filipe B, Vergote K, Agace William W, Clausen Björn E, Hammad H, Dalod M, Saeys Y, Lambrecht Bart N, Guilliams M (2016) IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells. Respect Immun 45(3):626–640. https://​doi.​org/​10.​1016/​j.​immuni.​2016.​08.​013CrossRef
28.
go back to reference Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh T, Honma K, Matsuyama T, Yui K, Tsujimura T, Standley DM, Nakanishi K, Nakai K, Akira S (2010) The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 11(10):936–944. https://doi.org/10.1038/ni.1920CrossRefPubMed Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh T, Honma K, Matsuyama T, Yui K, Tsujimura T, Standley DM, Nakanishi K, Nakai K, Akira S (2010) The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 11(10):936–944. https://​doi.​org/​10.​1038/​ni.​1920CrossRefPubMed
31.
go back to reference Metzger P, Kirchleitner SV, Kluge M, Koenig LM, Hörth C, Rambuscheck CA, Böhmer D, Ahlfeld J, Kobold S, Friedel CC, Endres S, Schnurr M, Duewell P (2019) Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. J Immuno Therapy Cancer 7(1):288. https://doi.org/10.1186/s40425-019-0778-7CrossRef Metzger P, Kirchleitner SV, Kluge M, Koenig LM, Hörth C, Rambuscheck CA, Böhmer D, Ahlfeld J, Kobold S, Friedel CC, Endres S, Schnurr M, Duewell P (2019) Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. J Immuno Therapy Cancer 7(1):288. https://​doi.​org/​10.​1186/​s40425-019-0778-7CrossRef
33.
go back to reference Hasenberg A, Hasenberg M, Mann L, Neumann F, Borkenstein L, Stecher M, Kraus A, Engel DR, Klingberg A, Seddigh P, Abdullah Z, Klebow S, Engelmann S, Reinhold A, Brandau S, Seeling M, Waisman A, Schraven B, Gothert JR, Nimmerjahn F, Gunzer M (2015) Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. Nat Methods 12(5):445–452. https://doi.org/10.1038/nmeth.3322CrossRefPubMed Hasenberg A, Hasenberg M, Mann L, Neumann F, Borkenstein L, Stecher M, Kraus A, Engel DR, Klingberg A, Seddigh P, Abdullah Z, Klebow S, Engelmann S, Reinhold A, Brandau S, Seeling M, Waisman A, Schraven B, Gothert JR, Nimmerjahn F, Gunzer M (2015) Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. Nat Methods 12(5):445–452. https://​doi.​org/​10.​1038/​nmeth.​3322CrossRefPubMed
37.
go back to reference Goldman M, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, Zhu J, Haussler D (2019) The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. BioRxiv. https://doi.org/10.1101/326470CrossRef Goldman M, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, Zhu J, Haussler D (2019) The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. BioRxiv. https://​doi.​org/​10.​1101/​326470CrossRef
Metadata
Title
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
Authors
Philipp Metzger
Sabrina V. Kirchleitner
Daniel F. R. Boehmer
Christine Hörth
Angelika Eisele
Steffen Ormanns
Matthias Gunzer
Maciej Lech
Kirsten Lauber
Stefan Endres
Peter Duewell
Max Schnurr
Lars M. König
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02605-9

Other articles of this Issue 10/2020

Cancer Immunology, Immunotherapy 10/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine